Ulipristal acetate (UPA)

DRUG2 trials

Sponsors

Allergan

Conditions

LeiomyomaUterine Hemorrhage

Phase 3

A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

CompletedNCT02147197

AllerganLeiomyoma, Uterine Hemorrhage

Start: 2014-03-31End: 2016-03-29Updated: 2019-04-30

A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas

CompletedNCT02147158

AllerganLeiomyoma, Uterine Hemorrhage

Start: 2014-01-29End: 2016-11-24Updated: 2019-06-04

Related Papers

Psychometric validation of the 1-month recall Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire (UFS-QOL).

2019-08-2315 citations

Health-Related Quality of Life With Ulipristal Acetate for Treatment of Uterine Leiomyomas

Obstetrics and Gynecology2019-04-0920 citations

Ulipristal Acetate for Treatment of Uterine Leiomyomas

Obstetrics and Gynecology2018-10-1039 citations

Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas

Obstetrics and Gynecology2018-02-0853 citations

51 Benign Endometrial Changes by Race and BMI With Ulipristal Acetate Treatment

American Journal of Clinical Pathology2018-01-01

Ulipristal Acetate Treatment of Uterine Fibroids in Black and Obese Women: Venus I Subgroup Analyses [28G]

Obstetrics and Gynecology2017-05-015 citations